Most hematological cancer-related relapses and deaths are caused by metastasis;thus,the importance of this process as a target of therapy should be considered.Hematological cancer is a type of cancer in which metaboli...Most hematological cancer-related relapses and deaths are caused by metastasis;thus,the importance of this process as a target of therapy should be considered.Hematological cancer is a type of cancer in which metabolism plays an essential role in progression.Therefore,we are required to block fundamental metastatic processes and develop specific preclinical and clinical strategies against those biomarkers involved in the metabolic regulation of hematological cancer cells,which do not rely on primary tumor responses.To understand progress in this field,we provide a summary of recent developments in the understanding of metabolism in hematological cancer and a general understanding of biomarkers currently used and under investigation for clinical and preclinical applications involving drug development.The signaling pathways involved in cancer cell metabolism are highlighted and shed light on how we could identify novel biomarkers involved in cancer development and treatment.This review provides new insights into biomolecular carriers that could be targeted as anticancer biomarkers.展开更多
基金Supported by Sanming Project of Medicine in Shenzhen,No. SZSM201512033Shenzhen Fund for Guangdong Provincial High-level Clinical Key Specialties,No. SZGSP012+1 种基金Shenzhen Key Medical Discipline Construction Fund,No. SZXK034Shenzhen Healthcare Research Project,No. SZLY2018015
文摘Most hematological cancer-related relapses and deaths are caused by metastasis;thus,the importance of this process as a target of therapy should be considered.Hematological cancer is a type of cancer in which metabolism plays an essential role in progression.Therefore,we are required to block fundamental metastatic processes and develop specific preclinical and clinical strategies against those biomarkers involved in the metabolic regulation of hematological cancer cells,which do not rely on primary tumor responses.To understand progress in this field,we provide a summary of recent developments in the understanding of metabolism in hematological cancer and a general understanding of biomarkers currently used and under investigation for clinical and preclinical applications involving drug development.The signaling pathways involved in cancer cell metabolism are highlighted and shed light on how we could identify novel biomarkers involved in cancer development and treatment.This review provides new insights into biomolecular carriers that could be targeted as anticancer biomarkers.
